News
Gene therapy increases factor IX activity in severe hemophilia B - Healio
www.healio.com
... [for] immune responses that require immunosuppression or may lead to a loss of efficacy,” Matt Kapusta, CEO of uniQure, said in the release.
uniQure Receives Frost & Sullivan Manufacturing Leadership Award
www.firmenpresse.de
-- Lexington, MA-based Gene Therapy Facility Recognized for Enabling Manufacturing Excellence --LEXINGTON, Mass
uniQure N.V.: uniQure Appoints Alexander Kuta as Senior Vice...
www.finanznachrichten.de
He will report to Matt Kapusta, Chief Executive Officer of uniQure, and will be based in the Company's Lexington, Massachusetts facility. "Alex has an accomplished track …
uniQure Receives Frost & Sullivan Manufacturing Leadership Award...
www.wallstreet-online.de
... in gene therapy and we are delighted that Frost & Sullivan has recognized our achievements in this regard," stated Matt Kapusta, chief executive officer of uniQure. …
sortiert nach Relevanz / Datum